Castalysis Bioscience
篆码生物
elsewhere's corpus does not cover Castalysis Bioscience as a subject in its own right. The name appears only in relations where it is partnered with Yan Yin Tech (衍因科技) on China's first CRISPR gene-design tool, per Qiming Venture Partners announcements from mid-2025 . No standalone profile — founding date, team, funding, or independent company description — is available in the retrieved material. The "Document Chunks (about the subject)" section is empty; the two chunks present (, ) discuss unrelated companies (Keyin Bio / 科因生物 and Guangyue Biotechnology / 光玥生物 respectively).
AI-generated — may contain errors, please verify.
Coverage
Qiming Portfolio Company Yanyin Technology Partners with HEC Pharm on Strategic AI Collaboration
The two parties will engage in in-depth collaboration on AI agent R&D, using the AI translation agent project as a starting point to develop solutions covering core scenarios including experimental design and IND filing, as well as AI laboratory automation robotics. Together, they will explore the deep application of AI technology across the full drug discovery and development pipeline, accelerating the globalization strategy of East Sunshine Pharmaceutical.
Qiming Venture Partners Weekly | Portfolio Company Updates and Funding News Vol. 21, 2025
Celebrating milestone moments with Qiming Venture Partners' portfolio companies
Qiming Venture Partners Portfolio Companies YanYin Technology and ZhuanMa Bio Launch China's First CRISPR Gene Design Tool
The two parties will jointly develop a next-generation CRISPR design application platform, deeply integrating Zuanma Biotech's cutting-edge gene editing technology with YanYin AI's cloud-based R&D platform. This collaboration will deliver unprecedented convenience, precision, and efficiency to CRISPR gene editing users worldwide, dramatically streamlining the design and analysis workflows for gene editing experiments.
